Following evaluation by the end-user, selected hybridoma lines will be cloned twice by limiting dilution and further selected for high antibody productivity. At each stage, supernatant will be forwarded to the investigators laboratory for evaluation.

Four sub-clones from each parental hybridoma line will be expanded and preliminary frozen stocks prepared in duplicate ampoules.

In consultation with the user, validated primary frozen stocks will then be prepared for banking and long-term storage. Following viability and mycoplasma testing, these stocks will be available for distribution to the primary investigator and, if appropriate, collaborating laboratories.